Skip to main content
SpringerLink
Log in

Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background: Docetaxel (DTX) has been shown to be a very active drug in both breast cancer (BC) and non-small-cell lung cancer (NSCLC). Irinotecan (CPT-11) is also active in NSCLC, and has shown promising antitumor activity in pretreated BC.Purpose: To define the MTDs of these two drugs given together every other week with the use of filgrastim support in pretreated BC and NSCLC patients.Patients and methods: Patients (aged 18–70 years, performance status ≤2) with advanced NSCLC or BC who had received at least one prior chemotherapy regimen were candidates for this phase I study. The starting DTX and CPT-11 doses were 60 mg/m2 and 80 mg/m2. Doses were alternately escalated at each step by 10 mg/m2 for both drugs. Filgrastim 300 μg/day was given subcutaneously from days 4 through 7 of each cycle.Results: From April 2000, 41 patients were included in the trial (27 BC, 14 NSCLC). All BC patients had received epirubicin plus paclitaxel (with or without cisplatin) as first-line treatment. Of the 14 NSCLC patients, 12 had received cisplatin-based first-line therapy, and 8 patients had been pretreated with paclitaxel. The dose escalation proceeded through five dose levels up to DTX and CPT-11 doses of 80 mg/m2 and 100 mg/m2, respectively. Overall, ten patients showed dose-limiting toxicity during the first cycle, diarrhea in seven and neutropenia in the remaining three. Considering all 218 cycles delivered, grade 3 or 4 neutropenia occurred in 14 patients (34%), with only one episode of neutropenic fever, while severe diarrhea was observed in 9 patients (23%). A total of 21 objective responses were registered (four complete) for an overall response rate of 51% [95% CI 35–67]. A major response was seen in 16 of the 27 BC patients (59%) and in 5 of the 14 NSCLC patients (36%).Conclusions: DTX and CPT-11 can be safely given together biweekly at adequate doses, with filgrastim support. In view of the promising activity data in both groups, phase II studies testing this combination in pretreated BC and NSCLC patients are ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adjei AA, Klein CE, Kastrissios M, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C (2000) Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol 18: 1116

    PubMed  CAS  Google Scholar 

  2. Bissery MC, Couteau C, Oulid-Aissa D (1997) Docetaxel in combination with Irinotecan: prediction of clinical maximum tolerated dose (abstract no. 773). Proc Am Soc Clin Oncol 16: 221a

    Google Scholar 

  3. Cameron It., Hardman WE (1999) Comparative efficacy of CPT-11, topotecan, doxorubicin and cisplatin against xenografts of colon, lung, and breast cancer cells in nude mice. Proc Am Assoc. Cancer Res 40: 109AB

    Google Scholar 

  4. Comela P, De Vita F, Mancarella S, De Lucia L, Biglietto M, Casaretti R, Farris A, Ianniello GP, Lorusso V, Avallone A, Carteni G, Leo SS, Catalano G, De Lena M, Comella G (2000) Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluororacil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II–III randomized trial. Ann Oncol 11: 1323

    Article  Google Scholar 

  5. Couteau C, Risse ML, Ducreux M, Lefresne-Soulas F, Riva A, Lebecq A, Ruffie P, Rougier P, Lokiec F, Bruno R, Armand JP (2000) Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J. Clin Oncol 18: 3545

    PubMed  CAS  Google Scholar 

  6. Fossella F, De Vote R, Kerr R, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Phase III trial of docetaxel 100, mg/m2 or 75 mg/m2 vs. vinorelbine-ifosfamide for non-small cell lung cancer patients previously treated with platinum based chemotherapy. J Clin Oncol 18: 2354

    PubMed  CAS  Google Scholar 

  7. Frasci G, Comella P, D'Aiuto G, Thomas R, Capasso I, Elmo M, Botti G, Cortino GR, Lapenta L, De Rosa V, Vallone P, Petrillo A, Comella G (2000) Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients. A parallel dose-finding study. Ann Oncol 11: 367

    Article  PubMed  CAS  Google Scholar 

  8. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10: 16

    PubMed  CAS  Google Scholar 

  9. Ikeda, H (2000) A pilot study of irinotecan hydrochloride for metastatic breast cancer. Efficacy as a salvage therapy. Gan To Kagaku Ryoho 27: 723

    PubMed  CAS  Google Scholar 

  10. Kaneda N, Yokokura T (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50: 1721

    PubMed  CAS  Google Scholar 

  11. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715

    PubMed  CAS  Google Scholar 

  12. Kaplan ES, Meier P (1958) Non-parametric estimation for incomplete observations. J Am Stat Assoc 53: 557

    Article  Google Scholar 

  13. Kawamoto Y, Aonuma M, Hirota Y (1991) Intracellular roles of SN-38, an active metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187

    Google Scholar 

  14. Knuuttila A., Ollikainen T, Halme M, Mali P, Kivisaari L, Linnainmaa K, Jekunen A, Mattson S (2000) Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma. A feasibility study. Anticancer Drugs 11: 257

    Article  PubMed  CAS  Google Scholar 

  15. Livingston RB, Ellis GK, Gralow JR, Edelman B, Yao TJ, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, Baselga J, Tong W, O'Donaghue M, Salvaggio R, Auguste L, Spriggs D, Norton L (1997) Dose-intensive vinorelbine with concurrent granulocyte-colony stimulating factor support in paclitaxel refractory metastatic breast cancer. J Clin Oncol 15: 1395

    PubMed  CAS  Google Scholar 

  16. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S (1992) CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 10: 1775.

    PubMed  CAS  Google Scholar 

  17. Masuda N, Fukuoka M, Negoro S, Yakada Y, Sugiura T, Ohashi Y, Ariyoshi Y, Nitani H (1999) Randomized trial comparing cisplatin and irinotecan vesus CDDP and vindesine versus CPT-11 alone in advanced non-small cell lung cancer. A multicenter phase ITT trial. Proc Am Soc. Clin Oncol 18: 1774

    Google Scholar 

  18. Masuda N, Negoro S, Kidoh S, Sugiura T, Nakagawa K, Saka H, Takada M, Niitani H, Fukuoka M (2000) Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small cell lung cancer. J Clin Oncol 18: 2996

    PubMed  CAS  Google Scholar 

  19. Miller AB, Hoogstraten B, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207

    Article  PubMed  CAS  Google Scholar 

  20. Nabholtz JM, Sean HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M (1999) Prospective randomised trial of docetaxel versus mitoycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline containing chemotherapy. J Clin Oncol 17:1413

    PubMed  CAS  Google Scholar 

  21. Ohe Y, Sasaki Y, Shinkai T (1992) Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972

    Article  PubMed  CAS  Google Scholar 

  22. Okishio K, Kudoh S, Himta K (1995) Schedule dependent additive effects of docetaxel and irinotecan in vitro. Proc Jpn J Cancer Res 86:219

    Google Scholar 

  23. Perez EA, Willman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhill SR (2002) Randomized phase II study of 2 schedules of irinotecan (CPT-11) for patients with refractory metastatic breast cancer: an NCCTG Cooperative Group study. Proc Am Soc Clin Oncol 21:52a

    Google Scholar 

  24. Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD (2001) Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every 2 weeks. Ann Oncol 12:1631

    Article  PubMed  CAS  Google Scholar 

  25. Sande JR, Verdirame J, Hillman S, Geyer S, Drevyanko T, Tazelaar H, Jett J, Adjei AA (2002) A phase II study of irinotecan and docetaxel in patients with recurrent non-small cell lung cancer (abstract no. 1295). Proc Am Soc Clin Oncol 21:324

    Google Scholar 

  26. Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, Baselga J, Tong W, O'Donaghue M, Salvaggio R, Auguste L, Spriggs D, Norton L (1996) Ninety-six hour paclitaxel infusion after progression during short paclitaxel exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877

    PubMed  CAS  Google Scholar 

  27. Shepherd F, Ramlau R, Mattson K, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Randomized study of taxotere versus best supportive care in non-small cell lung cancer patients previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095

    PubMed  CAS  Google Scholar 

  28. Shigeoka Y, Itoh K, Igarashi T, Ishizawa K, Saeki T, Fujii H, Minami H, Imoto S, Sasaki Y (2001) Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens. Jpn J Clin Oncol 31:370

    Article  PubMed  CAS  Google Scholar 

  29. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391

    Article  PubMed  CAS  Google Scholar 

  30. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D (1991) CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 14:341

    PubMed  CAS  Google Scholar 

  31. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA 3rd (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16:3362

    PubMed  CAS  Google Scholar 

  32. Van Oosterom AT (1995) Docetaxel (Taxotere): an effective agent in the management of secondline breast cancer. Semin Oncology 22 [6 Suppl 13]:22

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SICOG, c/o National Tumor Institute, Via M Semmola, 80131, Naples, Italy

    Giuseppe Frasci, Pasquale Comella, Renato Thomas, Maurizio Di Bonito, Liliana Lapenta, Immacolata Capasso, Gerardo Botti, Paolo Vallone, Vincenzo De Rosa, Giuseppe D'Aiuto & Giuseppe Comella

Authors
  1. Giuseppe Frasci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pasquale Comella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Renato Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maurizio Di Bonito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liliana Lapenta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Immacolata Capasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gerardo Botti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Paolo Vallone
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Vincenzo De Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giuseppe D'Aiuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Giuseppe Comella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Frasci.

Additional information

Published online: 26 September 2003

This work is presented on behalf of the Southern Italy Cooperative Oncology Group (SICOG), c/o National Tumor Institute of Naples, Italy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frasci, G., Comella, P., Thomas, R. et al. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study. Cancer Chemother. Pharmacol. 53, 25–32 (2004). https://doi.org/10.1007/BF02665349

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02665349

Keywords

Search

Navigation